Developer docs
API playgroundTry for free, no card

Search company profiles

Kemipharm

Full company profile

uuid004pzqf

Namestring
Kemipharm
Websiteurl
kemipharm.com
Company typeenum
Private
Founded yearstring
-
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
Markets served

Serves global market

Product category
Pharmaceuticals
Social media profiles1 record
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

No description of Kemipharm's core offering can be supported by the available source data. The company's website (kemipharm.com) currently displays only a HostGator hosting-provider placeholder page rather than content describing its products or services.

Differentiator
Functional benefit
Problem solved
No data
Peers4 records
TypeBroad incumbent
Description

Drug discovery and CMC development services provider with pharmaceutical chemistry capabilities, now part of Evotec. Overlaps a chemistry-led pharma services business targeting development-stage customers.

TypeBroad incumbent
Description

Global CDMO leader across small molecules, biologics, and cell & gene therapies. Relevant as a benchmark for scale and as the dominant incumbents a smaller chemistry-based manufacturer would compete against for contract volumes.

3Recipharm
TypeDirect peer
Description

European-headquartered pharmaceutical contract development and manufacturing organization (CDMO) offering solid-dose, sterile, and API production. Most directly relevant if Kemipharm operates as a Nordic/specialty pharma CDMO with chemistry-focused capabilities.

TypeDirect peer
Description

Small-molecule API and finished-dose contract manufacturer serving branded and generic pharma customers. Comparable to a specialty intermediates manufacturer anchored in chemistry ('kemi') production.

Market position
Customer concentration

Classification, Details

No data
Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kemipharm

Pharmaceuticalskemipharm.com

Kemipharm firmographics

Firmographics
Name
Kemipharm
Website
https://kemipharm.com
Company type
Private
Headcount range
11–50 employees
Ownership category
akta.pro rank

Kemipharm business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing

Kemipharm product offering

Product offering

Core offering

No description of Kemipharm's core offering can be supported by the available source data. The company's website (kemipharm.com) currently displays only a HostGator hosting-provider placeholder page rather than content describing its products or services.

Differentiator

Problem solved

Functional benefit

Kemipharm technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Kemipharm competitors and assessment

Company assessment

Broad incumbents

  • Aptuit (Evotec): Drug discovery and CMC development services provider with pharmaceutical chemistry capabilities, now part of Evotec. Overlaps a chemistry-led pharma services business targeting development-stage customers.
  • Lonza: Global CDMO leader across small molecules, biologics, and cell & gene therapies. Relevant as a benchmark for scale and as the dominant incumbents a smaller chemistry-based manufacturer would compete against for contract volumes.

Direct peers

  • Recipharm: European-headquartered pharmaceutical contract development and manufacturing organization (CDMO) offering solid-dose, sterile, and API production. Most directly relevant if Kemipharm operates as a Nordic/specialty pharma CDMO with chemistry-focused capabilities.
  • Cambrex: Small-molecule API and finished-dose contract manufacturer serving branded and generic pharma customers. Comparable to a specialty intermediates manufacturer anchored in chemistry ('kemi') production.

Market position

Customer concentration

Kemipharm social profiles

Digital presence

Kemipharm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kemipharm leadership team

Management profile

Number of profiles

Kemipharm funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kemipharm M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kemipharm

What does Kemipharm do?

No description of Kemipharm's core offering can be supported by the available source data. The company's website (kemipharm.com) currently displays only a HostGator hosting-provider placeholder page rather than content describing its products or services.

When was Kemipharm founded?

Kemipharm was founded in -1. It employs 11 to 50 people.

Who are Kemipharm's main competitors?

Broad incumbents on record are Aptuit (Evotec) and Lonza. Direct peers are Recipharm and Cambrex.

Does Kemipharm have an API?

No public API is recorded for Kemipharm.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireKemPharm Announces Appointment of Christopher Posner as New Independent DirectorKemPharm appointed Christopher Posner, president and CEO of Cara Therapeutics, as an independent director. He brings over 20 years of pharmaceutical experience, including roles at LEO Pharma and Bristol-Myers Squibb. The company anticipates a Phase 2 trial for KP1077 and an NDA resubmission for arimoclomol in 2023.GlobeNewswireAdjusted financial outlook for 2022Orphazyme A/S adjusted its 2022 outlook, separating continuing and discontinued operations. It expects a loss from continuing operations of DKK 40-45 million and a profit from the asset sale to KemPharm of DKK 87.4 million, with over DKK 30 million in cash.GlobeNewswireKemPharm to Present at the Canaccord Genuity 42nd Annual Growth ConferenceKemPharm's Executive Chairman Richard W. Pascoe will present at the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, in Boston. The company will also host one-on-one meetings and a live webcast of the presentation.GlobeNewswireKemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases PipelineKemPharm agreed to acquire arimoclomol from Orphazyme for $12.8 million, including a $5.2 million reserve liability. The company plans to refil the FDA NDA for Niemann-Pick disease type C as early as Q1 2023, with the transaction expected to close by June 1, 2022.GlobeNewswireKemPharm, Inc. Announces Authorization of $50 Million Share Repurchase ProgramKemPharm's board authorized a $50 million share repurchase program, effective immediately through December 31, 2023. The authorization represents about 18% of the company's market capitalization. Repurchases will be funded from working capital and operating cash flow.GlobeNewswireKemPharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of “Higher-Dose SDX”KemPharm announced top-line results from a Phase 1 trial of serdexmethylphenidate (SDX) at doses higher than those studied with AZSTARYS. The trial found doses up to 600 mg were well-tolerated, with dose-proportional d-MPH exposure and biological effects suggesting potential for idiopathic hypersomnia and stimulant use disorder. KemPharm expects to update its SDX development plan in early Q1 2022.GlobeNewswireKemPharm, Inc. Announces Uplisting to The Nasdaq Global Select MarketKemPharm announced its shares will list on the Nasdaq Global Select Market, with trading starting October 19, 2021 under ticker KMPH. The company cited its growth and the market launch of AZSTARYS, its first differentiated ADHD medication, as key factors. The exchange's 1,450 stocks meet strict financial and governance standards.GlobeNewswireKemPharm, Inc. Announces Orange Book Listing for Six Patents Covering Serdexmethylphenidate (SDX) and Confirmation of NCE StatusKemPharm announced that six U.S. patents covering serdexmethylphenidate (SDX) are listed in the FDA Orange Book, confirming SDX as a new chemical entity (NCE) with five years of market exclusivity. The listing also protects AZSTARYS, the FDA-approved ADHD treatment containing SDX, from patent infringement.PR NewswireThinking about buying stock in Humanigen, Marathon Oil, KemPharm, GoHealth, or SRAX Inc?InvestorsObserver issued PriceWatch Alerts for stocks including Humanigen, Marathon Oil, KemPharm, GoHealth, and SRAX Inc. The alerts are based on a proprietary scoring system evaluating short-term technical, long-term technical, and fundamental factors to determine investment suitability. This serves as an informational notice directing investors to view specific ratings for these tickers.PR NewswireThinking about buying stock in Ovid Therapeutics, KemPharm, Super League Gaming, Heat Biologics, or TherapeuticsMD?InvestorsObserver issued PriceWatch Alerts for Ovid Therapeutics, KemPharm, Super League Gaming, Heat Biologics, and TherapeuticsMD on March 3, 2021. The alerts utilize a proprietary scoring system that evaluates short-term technical, long-term technical, and fundamental factors to determine investment suitability. This release serves as a routine distribution of market analysis data from the financial information provider.